Last reviewed · How we verify
BARICITINIB
Baricitinib is a marketed drug with a key composition patent expiring in 2028. Its primary strength lies in its established market presence and revenue generation. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | BARICITINIB |
|---|---|
| Drug class | Janus Kinase Inhibitor [EPC] |
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 2017 |
Approved indications
Common side effects
- Overall Infections
- Upper respiratory tract infection
- Viral upper respiratory tract infection
- Urinary tract infection
- Bronchitis
Serious adverse events
- Serious Infections
- Pneumonia
- Herpes zoster
- Tuberculosis
- Disseminated tuberculosis
- Opportunistic Infections
Key clinical trials
- Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis (PHASE1)
- Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID (PHASE3)
- A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE) (PHASE3)
- Efficacy and Safety of Telitacicept Combined With Baricitinib for Refractory Rheumatoid Arthritis
- Baricitinib in the Treatment of New-onset Juvenile Dermatomyositis (MYOCIT) (PHASE2)
- Baricitinib for Reduction of HIV - CNS (PHASE2)
- Efficacy and Safety of Baricitinib in Oral Lichen Planus: a Proof-of-Concept Study (PHASE2)
- A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BARICITINIB CI brief — competitive landscape report
- BARICITINIB updates RSS · CI watch RSS